Case report demonstrates recurrent isolated skin relapses of ALK-negative anaplastic large cell lymphoma in a pediatric patient, highlighting challenges in distinguishing systemic from primary...
We present the case of a 10‐year‐old female with anaplastic lymphoma kinase protein (ALK) negative systemic anaplastic large cell lymphoma (ALCL) with cutaneous manifestations that achieved complete remission after multi‐agent chemotherapy. Approximately 6 months after remission, the patient experienced a relapse of ALK‐negative ALCL confined exclusively to the skin. Four months after completing salvage therapy, she developed a second isolated cutaneous relapse. This case highlights the diagnostic challenge of distinguishing systemic ALCL from primary cutaneous ALCL and other primary cutaneous CD30+ lymphoproliferative disorders.
No takes yet. Share an insight, caveat, or question.
Coffman et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: